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InTroduCTIon
Many cardiovascular drugs in the pipeline will fail to 
demonstrate a clear clinical benefit when evaluated in 
large-scale clinical outcome trials, which are costly, 
require lengthy follow-up and can potentially expose 
patients to unforeseen risks. There exists an enor-
mous gap between early mechanistic studies demon-
strating proof-of-principle drug efficacy in preclinical 
models and successful translation of these therapies 
into everyday clinical practice. To help overcome this 
challenge, cardiovascular imaging techniques can be 
applied to quantify early changes in disease severity 
owing to drug intervention, or lack thereof, with the 
aim of informing subsequent clinical outcome trials. 
This approach can be used to direct valuable resources 
towards development of drugs most likely to provide 
real clinical impact. The rationale here is that ‘surro-
gate’ imaging outcomes can be powered using far 
less subjects than clinical outcomes in drug trials, as 
each participant will contribute an imaging endpoint 
regardless of whether they then go on to develop a 
clinical event. In addition, drug efficacy can be more 
rapidly tested using imaging markers as there is no 
need to wait long periods of time for clinical outcomes 
to occur.
Imaging endpoints in clinical trials might also be 
used in the future to identify specific subgroups of 
patients who are more likely than others to respond 
to targeted pharmacotherapies in cardiovascular 
disease—the so-called precision medicine. Indeed, 
better methods are needed to identify those patients 
with cardiovascular disease who are most at risk of 
future or recurrent, clinical events despite secondary 
prevention. Many of these patients will have ‘residual’ 
on-treatment risk and could benefit from higher inten-
sity lipid lowering or anti-inflammatory therapies 
currently under evaluation in atherosclerosis. Mecha-
nisms underlying on-treatment residual risk are widely 
heterogeneous and patient specific, with different 
disease substrates (ie, thrombotic tendency, lipid accu-
mulation and inflammation) contributing in varying 
degrees to an individual’s future cardiovascular risk. 
Consequently, applying targeted antiatherosclerotic 
drugs on top of standard therapies broadly in unse-
lected patient populations is likely to produce at most 
a modest impact on clinical outcomes. This article will 
discuss the potential scope of imaging to improve drug 
efficacy testing of current and emerging disease-modi-
fying therapies in atherosclerosis.
ImagIng EndpoInTs
The ideal imaging endpoint for use in any cardio-
vascular drug trial should be easily measurable and 
highly reproducible, with sound biological rationale 
and strong prognostic link to important clinical 
outcomes. Importantly, an imaging biomarker should 
also reflect and track the mechanism of the tested 
drug. For example, measurement of plaque lipid 
content would be an appropriate biomarker for 
studying lipid-lowering therapies. The relative 
change in response to drug intervention for an ideal 
imaging endpoint should also be detected within a 
relatively short time-frame. Methods for quantifi-
cation of atherosclerotic disease severity have been 
comprehensively reviewed elsewhere1 2; here we 
focus on their ability to predict clinical events.
Validation of imaging for risk prediction
Among the most widely used imaging endpoints 
for cardiovascular drug trials are arterial inflam-
mation, vascular intima media thickness (IMT), 
plaque burden (or atheroma volume) and plaque 
morphology.
Vascular inflammation is the earliest modifiable 
link between clinical cardiovascular risk factors and 
disease activity that can be detected using imaging. 
When imaged using 18F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET), arterial 
inflammation can offer prognostic information 
beyond clinical risk factors, including Framingham 
risk score, with an increased HR of 2.9–4.7 for the 
highest risk groups in large retrospective analyses.3 4
IMT provides a measure of local atherosclerotic 
burden, including early subclinical disease, which 
has also been correlated with risk of future myocar-
dial infarction (MI) and stroke.5 6 However, the link 
between vascular IMT and future cardiovascular 
risk remains unproven,7 and carotid IMT might 
represent vascular changes arising from arterial 
hypertension rather than a direct marker of athero-
sclerosis per se.8
Total plaque burden is in fact the strongest prog-
nostic indicator that has been identified in large 
prospective imaging trials.9–11 While the presence 
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of high-risk plaque features associated with the 
histological appearance of ‘vulnerable’ rupture-
prone thin-cap fibroatheromas (TCFAs) are also 
predictors of major adverse cardiovascular events 
(MACE),10–12 it remains unclear whether identifying 
individual plaque characteristics is of incremental 
value to simpler assessments of plaque burden, 
as at the plaque level, this approach is limited by 
poor positive predictive value.13 Indeed, the vast 
majority of coronary artery TCFAs identified using 
virtual histology (VH)-intravascular ultrasound 
(IVUS) do not go on to cause clinical events because 
they either heal or rupture silently without clinical 
sequelae.14
New imaging techniques may offer opportunities 
to measure plaque lipid content, both invasively 
using near infrared spectroscopy and non-invasively 
using carotid MRI with T2 mapping.15 Quantifica-
tion of pericoronary adipocyte content and inflam-
mation could provide additional surrogate markers 
of cardiovascular risk for use in clinical drugs trials 
in the future.16
Degree of intraluminal stenosis, ischaemic 
burden and coronary artery calcification (CAC) 
are additional imaging markers that have been 
tested as surrogate endpoints in drug trials. While 
angiographic stenosis severity and functional isch-
aemia are among the most important factors used 
to guide everyday clinical management decisions, 
particularly when contemplating coronary revascu-
larisation, they represent a late stage in the disease 
process that is not easily modifiable by drug inter-
vention. Moreover, although there is a well-estab-
lished association between ‘flow-limiting’ coronary 
disease and hard clinical outcomes, this relationship 
might not be causal. Indeed, reversal of coronary 
ischaemia with drug intervention and percutaneous 
coronary stenting in patients with stable angina 
does not appear to reduce rates of long-term MI 
or death.17 The presence of haemodynamically 
obstructive coronary stenoses might instead simply 
act as a surrogate of plaque burden. CAC scoring is 
another clinical risk stratification tool that provides 
an estimate of overall coronary atherosclerotic 
burden (including the burden of less stable plaques), 
with strong incremental link to clinical outcomes.18 
However, the clinical significance of change in 
coronary calcification owing to drug intervention 
has yet to undergo specific validation as a prog-
nostic biomarker and increases in coronary artery 
macrocalcification as observed in patients treated 
with statins might, in fact, be protective rather than 
harmful.19
other considerations
It is important to acknowledge that any perceived 
prognostic benefit of surrogate imaging markers, 
which has been inferred from observational studies, 
cannot stand alone for drug approval. Moreover, 
this approach does not account for the influence 
of confounding factors, including multiple drug 
effects and cannot replace the need for a prospec-
tive controlled clinical trial to test drug safety.20 
Exposure to ionising radiation, additional risks 
associated with invasive imaging procedures and 
local accessibility to imaging technology are other 
factors to consider when choosing between surro-
gate imaging endpoints for cardiovascular drug 
trials. While plaque volume and composition can 
be more precisely quantified using invasive versus 
non-invasive coronary imaging, it is worth bearing 
in mind that there is also a high ~25% partici-
pant dropout in contemporary invasive imaging 
studies.21 In addition, the concept of an overall 
‘barometer’ of disease severity that might be modi-
fiable with drug intervention can be more readily 
attained using non-invasive than invasive imaging, 
for example, with PET or MRI, where the entire 
vascular bed can be imaged simultaneously.
usE of ImagIng for TEsTIng drug EffICaCy 
In aTHErosCLErosIs
Here we discuss how various imaging biomarkers 
have been applied in clinical drug trials to study the 
efficacy of disease modifying therapies in athero-
sclerosis, including both long-established and newly 
tested lipid-lowering and anti-inflammatory agents.
Lipid-lowering and other drugs affecting 
cholesterol
Statins
Statins reduce low-density lipoprotein cholesterol 
(LDL-c) through inhibition of β-Hydroxy β-meth-
ylglutaryl-CoA (HMG-CoA (HMG CoA)reductase 
and have been proven in landmark clinical trials 
to dramatically reduce the incidence of cardio-
vascular events in a range of individuals,22 with 
greater benefit seen for intensive versus moderate 
or low-dose therapy in patients with stable angina 
or previous MI.23 24 In fact, patients treated with 
statins who achieve LDL-c lowering of 2–3 mmol/L 
are expected to have a 40%–50% reduction in 
cardiovascular risk regardless of their baseline 
lipid profile.25 While the clinical benefits of statins 
have long been proven, contemporary imaging 
studies have nonetheless contributed important 
mechanistic insights revealing the multiple effects 
of statins on the arterial wall and atherosclerotic 
plaques. Collectively, these studies have demon-
strated that treatment with statins can result in 
reduction of arterial inflammation, IMT, plaque 
volume and lipid content of the necrotic core, as 
well as a modest increase in angiographic luminal 
diameter and increased fibrous cap thickness and 
arterial macrocalcification contributing to plaque 
stability.
Dampening of arterial inflammation has been 
demonstrated in several studies of statins using 
18F-FDG PET and ultrasmall superparamagnetic 
iron oxide (USPIO) nanoparticle-enhanced MRI. 
For example, ~11% reduction in the inflamma-
tory 18F-FDG PET signal was observed in a study 
of statin-naïve patients treated with high-inten-
sity atorvastatin after 12 weeks.26 Statin-induced 
dampening of arterial inflammation measured 
by 18F-FDG PET is associated with increases in 
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high-density lipoprotein cholesterol (HDL-c) and 
the inflammatory biomarker matrix metallopro-
teinase-9.27 28 In the Atorvastatin Therapy: Effects 
on Reduction of Macrophage Activity study, signifi-
cant reductions in carotid artery inflammation were 
also found using USPIO-enhanced MRI in patients 
treated with high-intensity statins.29
Regression of arterial IMT has been reliably 
observed in statin trials. In the Regression Growth 
Evaluation Statin study, treatment with pravastatin 
resulted in significant reduction in carotid and 
femoral IMT measured by B-mode ultrasound in 
patients with coronary artery disease.30 Similarly, 
the randomised placebo controlled Measuring 
Effects on Intima-Media Thickness: an Evaluation 
of Rosuvastatin study of 984 middle-aged individ-
uals with low Framingham risk scores but evidence 
of subclinical atherosclerosis showed a reduction in 
ultrasound measured carotid IMT after treatment 
with rosuvastatin.31 Moreover, the beneficial effect 
of statins on IMT has also been demonstrated in 
several studies using MRI of the carotid arteries 
and the aorta, which also suggested that this drug 
therapy induces vascular remodelling by reducing 
atherosclerotic burden without affecting the 
lumen.32 33
Reduction in coronary artery plaque burden 
following treatment with statins has been demon-
strated by numerous clinical studies using IVUS. 
Among the many longitudinal IVUS studies 
undertaken to investigate the effects of statins 
on coronary artery atherosclerosis are A Study to 
Evaluate the Effect of Rosuvastatin on Intravas-
cular Ultrasound-Derived Coronary Atheroma 
Burden (ASTEROID),34 Reversal of Atheroscle-
rosis with Aggressive Lipid Lowering,35 Early 
Statin Treatment in Patients With Acute Coronary 
Syndrome,36 Integrated Biomarkers and Imaging 
Study-437 and Study of Coronary Atheroma by 
Intravascular Ultrasound: Effect of Rosuvastatin 
vs. Atorvastatin.21 Overall, these studies showed 
that high-intensity statin therapy is associated 
with significant reduction in percentage atheroma 
volume irrespective of baseline LDL-c or high-sensi-
tivity C-reactive protein (hsCRP) levels. Moreover, 
a study including IVUS data from 4477 patients 
with stable angina demonstrated that individuals 
with high-risk plaques had accelerated progres-
sion of atheroma burden, which was modifiable in 
patients taking statins.38
Numerous imaging studies have shown that 
statins also induce favourable effects on plaque 
morphology. For example, in a study of 33 patients 
imaged using carotid MRI with follow-up over 
3 years, significant reductions of lipid-rich necrotic 
core (figure 1), with accompanying increases in 
stabilising fibrous tissue, were observed in patients 
treated with intensive lipid-lowering including ator-
vastatin.39 Other studies using MRI have confirmed 
reductions in carotid plaque lipid-rich necrotic core 
and aortic plaque volume with rosuvastatin.40 41 
High-intensity statin treatment was also associated 
with a reduction in coronary plaque necrotic core 
volume and number of TCFAs identified using 
VH-IVUS in several drug trials, including the Statin 
and Atheroma Vulnerability Evaluation study.42 43
Several trials have evaluated the effects of statins 
on fibrous cap thickness using optical coher-
ence tomography (OCT). In the Effect of Ator-
vastatin on Fibrous Cap Thickness on Coronary 
Atherosclerotic Plaque as Assessed by Optical 
Coherence Tomography study, increased fibrous 
cap thickness measured by OCT occurred in 
correlation to reductions in LDL-c, inflammatory 
biomarkers and OCT-defined macrophage content 
(figure 2).44 In other OCT studies, patients treated 
figure 1 MRI of carotid lipid-rich necrotic core depletion after lipid-lowering therapy. (A) Graph showing significant regression of carotid artery 
lipid-rich necrotic core (LRNC) measured by serial MRI in a study of 33 individuals followed up over 3 years; representative MR images from this study 
at (B) baseline and (C) 3 years after lipid-lowering therapy demonstrating regression of the LRNC (arrows). Figure adapted from Zhao et al. JACC 
Cardiovascular Imaging 2011.39
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with high-intensity statins had smaller lipid arcs 
and greater fibrous cap thickness compared with 
those on lower dose or no statins.45 46 Significant 
regression of coronary plaque lipid core content 
following treatment with rosuvastatin was also seen 
in the Reduction in Yellow Plaque by Aggressive 
Lipid lowering therapy (YELLOW) study using near 
infrared spectroscopy.47
Angiographic measurement of luminal narrowing 
has also been tested as a surrogate marker in drug 
trials evaluating the effects of statins. In the Multi-
centre Anti-Atheroma Study (MAAS) trial, simvas-
tatin resulted in a 2.6% increase in mean luminal 
diameter compared with placebo, with less patients 
showing angiographic disease progression in the 
treatment group.48 However, this surrogate marker 
was not correlated with extent of LDL-c change, 
and there was no difference in clinical outcomes 
between groups after 4 years. In a predefined 
substudy of the ASTEROID trial, a ~1% reduction 
in mean per cent diameter stenosis was observed 
using quantitative IVUS in patients treated with 
high-dose rosuvastatin, despite >50% reduction in 
LDL-c.49
Studies using serial CT coronary angiography 
(CTCA) scanning have also shown that statins can 
slow progression of low attenuation and non-cal-
cified plaques in patients with stable coronary 
disease.50 51 Indeed, the Attempts at Plaque Vulner-
ability Quantification with Magnetic Resonance 
Imaging Using Noncontrast T1-weighted Tech-
nique pilot study showed significant reduction in 
low attenuation plaque volume and percentage 
total atheroma volume measured by CTCA, as well 
as decreased plaque to myocardial signal intensity 
on T1-weighted MRI (a marker of high-risk plaque) 
figure 2 OCT imaging of fibrous cap thickening after statin treatment. (A) Graph showing per cent change in fibrous cap thickness and lipid arc 
measured by OCT in a study of 60 patients with unstable angina treated with atorvastatin 20 mg (red) or 5 mg (blue) for 12 months; representative 
OCT images from this study at (B) baseline and (C) 12 months showing increased fibrous cap thickness after treatment with atorvastatin. Figure 
adapted from Komukai et al. J Am Coll Cardiol 2014.44 OCT, optical coherence tomography.
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following 12 months of treatment with statins 
(figure 3).52 However, in a randomised, double-
blinded, multicentre trial including 471 patients 
with moderate CAC and without high-grade 
stenoses, statins were not able to attenuate progres-
sion of coronary artery macrocalcification.53 In fact, 
a paradoxical increase in dense calcific volume has 
been observed using CTCA in patients treated with 
high-intensity rosuvastatin after acute MI.54 This 
finding has been confirmed by a post hoc analysis 
of IVUS data from eight prospective randomised 
trials including 3495 patients, which showed 
increased plaque calcification following treatment 
with statins.55
Ezetimibe
As a second-line therapy for patients who are 
intolerant of statins or unable to achieve suffi-
cient LDL-c reduction with statins alone, ezetimibe 
lowers LDL-c by reducing intestinal absorption of 
cholesterol. Ezetimibe has been shown to reduce 
cardiac events by a modest 2% compared with 
placebo when added to simvastatin in patients with 
acute coronary syndrome.56 This relatively small 
prognostic benefit compared with the large benefit 
afforded by statins might explain why imaging 
studies performed in patients treated with ezetimibe 
have shown somewhat mixed results.
In the Ezetimibe and Simvastatin in Hypercholes-
terolemia Enhances Atherosclerosis Regression and 
Stop Atherosclerosis in Native Diabetics studies, 
ezetimibe did not significantly reduce carotid IMT 
when added to statins in patients with familial 
hypercholesterolaemia or diabetes mellitus, respec-
tively, despite additional LDL-c lowering.57 58 While 
in the Plaque Regression With Cholesterol Absorp-
tion Inhibitor or Synthesis Inhibitor Evaluated by 
Intravascular Ultrasound study, the combination of 
high-dose atorvastatin plus ezetimibe resulted in 
greater regression in atheroma volume determined 
by IVUS than statins alone (figure 4), this difference 
failed to meet the predefined non-inferiority margin 
of 3%.59 In contrast, another study showed that 
the addition of ezetimibe to fluvastatin resulted in 
significantly reduced lipid arc and increased fibrous 
cap thickness by ~0.04 mm measured using OCT.60
Evidence from clinical trials using intravascular 
imaging also suggests that treatment with ezetimibe 
does not significantly alter plaque composition 
when added to statin therapy, despite additional 
reductions in LDL-c and plaque volume. Both the 
Virtual Histology of Atherosclerosis Regression 
During Atorvastatin and Ezetimibe Administration 
and Effect of Ezetimibe on Stabilization and Regres-
sion of Intracoronary Plaque studies showed no 
significant differences in plaque composition and 
stabilisation between patients randomised to statin 
plus ezetimibe versus standard therapy, or statin 
monotherapy, using serial IVUS imaging over the 
duration of these studies.61 62
Other drugs affecting cholesterol
Other cholesterol-modifying therapies tested using 
surrogate imaging markers include niacin and 
cholesteryl ester transfer protein (CETP) inhibitors 
(eg, dalcetrapib). While these studies mostly showed 
little or no beneficial effect on imaging endpoints, 
importantly, these findings predicted the negative 
results of the large-scale clinical outcome trials. The 
effects of the proprotein convertase subtilisin-kexin 
figure 3 Effect of statins on T1-weighted MRI high-intensity plaques. (A) Graph showing significant reduction in T1-weighted MRI signal intensity 
in a study of 48 patients with coronary artery disease treated with high-intensity pivastatin compared with the propensity matched control group 
of patients with coronary disease not treated with statins; (b) representative image of a high-intensity proximal left anterior descending coronary 
artery plaque identified in this study using T1-weighted MRI, with (d) reduction in signal intensity after statin treatment; CTCA imaging of the same 
artery showing low-attenuation plaque and positive remodelling in the area of high-intensity on MRI (C) before and (E) after statin therapy showing 
reduction in plaque volume. Figure adapted from Noguchi et al. J Am Coll Cardiol 2015.52 CTCA, CT coronary angiography.
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9 (PCSK9) inhibitor evolocumab on coronary 
atherosclerosis has also been studied using imaging.
Among other effects on cholesterol, niacin acts 
primarily by increasing HDL-c ~20%. A meta-anal-
ysis of trials performed before statins became stan-
dard of care showed significant benefit on clinical 
outcomes and imaging biomarkers, including 
carotid IMT.63 High-dose modified release niacin 
also showed slight reductions in carotid artery wall 
area measured by MRI in statin-treated patients 
in the Oxford Niaspan study,64 as well as signifi-
cant reduction in carotid IMT in patients without 
diabetes in the Arterial Biology for the Investiga-
tion of the Treatment Effects of Reducing Choles-
terol)-2 (ARBITER) study, and in the ARBITER 
6-HALTS (HDL and LDL treatment strategies) study 
with greater effect than ezetimibe.65 However, in 
the National Institute on Aging plaque study addi-
tion of niacin to statins did not reduce carotid wall 
volume assessed by MRI66; a finding that echoes 
contemporary clinical outcome data showing no 
added clinical benefit for niacin in patients treated 
with statins and ezetimibe.67 68
CETP inhibitors also act primarily by raising 
HDL-c. Torcetrapib is a CETP inhibitor that was 
withdrawn from the market due to concerns about 
off-target toxicity leading to raised systolic blood 
pressure and increased cardiovascular events.69 
In the Investigation of Lipid Level Management 
Using Coronary Ultrasound to Assess Reduction 
in Coronary Atherosclerosis by CETP inhibition 
and HDL elevation study of 1188 patients with 
coronary artery disease imaged using serial IVUS, 
the addition of torcetrapib to atorvastatin did not 
significantly change the percent atheroma volume 
compared with atorvastatin monotherapy.70 The 
Rating Atherosclerotic Disease Change by Imaging 
with a New CETP Inhibitor-1 (RADIANCE-1) 
and RADIANCE-2 studies also showed that torce-
trapib did not reduce progression of carotid IMT 
in patients with familial hypercholesterolaemia 
and mixed lipidaemia.71 72 Similarly, dalcetrapib 
showed only nominal reduction in arterial 18F-
FDG PET signals and carotid wall area, and no 
change in vascular calcification, in the Safety and 
efficacy of dalcetrapib on atherosclerotic disease 
figure 4 LDL cholesterol lowering versus IVUS-defined atheroma volume. Graph showing correlation between low-density lipoprotein (LDL) 
cholesterol and percentage atheroma volume measured in drug trials using intravascular ultrasound (IVUS). Figure from Tsujita et al, J Am Coll Cardiol 
2015.59 ASTEROID, A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden; LDL-c, low-density 
lipoprotein cholesterol; PRECISE-IVUS, Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular 
Ultrasound; REVERSAL, Reversal of Atherosclerosis with Aggressive Lipid Lowering; SATURN, Study of Coronary Atheroma by Intravascular Ultrasound: 
Effect of Rosuvastatin vs. Atorvastatin.
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using novel non-invasive multimodality imaging 
(Dal-PLAQUE) study. Dalcetrapib also failed to 
improve clinical outcomes in the Effects of Dalce-
trapib in Patients with a Recent Acute Coronary 
Syndrome (Dal-OUTCOMES) study, which was 
terminated early for futility (figure 5).73–75
PCSK9 inhibitors are human monoclonal 
antibodies that inactivate the enzyme PCSK9, 
preventing LDL-receptor degradation and reducing 
serum LDL-c by increasing its uptake into hepato-
cytes. In the randomised placebo-controlled 
Global Assessment of Plaque Regression with a 
PCSK9 Antibody as Measured by Intravascular 
Ultrasound (GLAGOV) trial that included data 
from 968 patients with coronary artery disease 
undergoing coronary angiography in 197 hospi-
tals, the PCSK9 inhibitor evolocumab resulted 
in a modest ~1% reduction in plaque volume 
measured by IVUS (figure 6).76 Similarly, in a 
Cochrane review of clinical outcome trials evalu-
ating PCSK9 inhibitors, a modest <1% reduction in 
cardiovascular events was demonstrated, despite a 
marked ~54% reduction in LDL-c compared with 
placebo.77 Results of the GLAGOV VH substudy, 
presented at the 2017 European Society of Cardi-
ology Congress, showed that the addition of evolu-
cumab to statin therapy did not significantly alter 
plaque composition measured by VH-IVUS (calcific, 
fibrofatty, fibrous or necrotic core volume), when 
compared with placebo.78
These modest effects coupled with little or no 
effect on all-cause mortality when applied to unse-
lected patient cohorts,77 makes it difficult to justify 
the widespread use of expensive PCSK9 inhibi-
tors. Indeed, the annual cost of a PCSK9 inhibitor 
(~$14 350) does not meet generally acceptable incre-
mental cost-effectiveness thresholds.79 However, it 
is likely that higher risk cohorts would gain greater 
absolute clinical benefit, highlighting a potential 
role for imaging and other biomarkers to select 
those patients most likely to respond to treatment.80 
Importantly, the Further Cardiovascular Outcomes 
Research with PCSK9 Inhibition in Subjects with 
Elevated Risk trial showed a significant reduction in 
cardiovascular events compared with placebo (9.8% 
vs 11.3%, p<0.001) in patients with atherosclerotic 
cardiovascular disease and raised LDL ≥1.8 mmol/L 
despite statin therapy.81 The ongoing A RaNdomized 
Double-blInd Placebo ConTrolled Study Character-
izing THe Effects of PCSK9 Inhibition On Arterial 
Wall Inflammation in Patients With Elevated Lp(a), 
NCT02729025 study will determine whether evolu-
cumab can reduce arterial inflammation measured by 
18F-FDG PET in a cohort of patients with raised Lp(a) 
and LDL-c at baseline.
anti-inflammatory drugs
For decades now, we have known that atheroscle-
rosis is an inflammatory condition and not merely 
a disease of lipid dysregulation. Local and systemic 
inflammatory networks fuel every stage of the 
disease process from initial lesion formation, to the 
progression, destabilisation, rupture and healing of 
advanced atherosclerotic plaques.82 Accordingly, 
a new wave of anti-inflammatory therapies are in 
development for the management of atherosclerosis 
targeted to a range proinflammatory pathways and 
mediators. In several instances, imaging has proven 
useful as an early marker of drug efficacy, or lack 
thereof, and again, it holds promise in identifying 
the patients most likely to benefit from these expen-
sive or potentially toxic treatments.
Drugs used in systemic inflammatory diseases
Several disease-modifying and biological agents 
currently used for the treatment of chronic inflam-
matory diseases might be useful for treatment of 
atherosclerosis, including methotrexate, colchi-
cine, tumour necrosis factor-α (TNFα) inhibi-
tors and rituximab. Intriguingly, in a prospective 
controlled study of patients with severe psoriasis 
treated with anti-TNFα therapies or the inter-
leukin (IL)-12/IL-13 inhibitor ustekinumab, these 
anti-inflammatory therapies halted progression 
of CAC score but not luminal narrowing assessed 
by CTCA over a 13-month period.83 Anti-TNFα 
therapy has also been shown to reduce arterial 
IMT in patients with psoriasis who did not have 
calcified atherosclerotic plaques84 and reduce 
aortic 18F-FDG inflammatory signals in patients 
with rheumatoid arthritis.85 In another study of 
55 women with rheumatoid arthritis and without 
overt cardiovascular disease who were treated 
with rituximab, a monoclonal antibody to CD20 
on B cells, a significant 9% reduction in carotid 
IMT was seen in those patients whose arthritis 
also responded to treatment.86 A prospective 
study of rituximab in patients with ST elevation 
MI is ongoing (NCT03072199).
Novel anti-inflammatory drugs for atherosclerosis
Among the many emerging therapies being eval-
uated for the treatment of atherosclerosis with 
anti-inflammatory actions include drugs targeted 
at p38 mitogen-activated protein kinase (MAPK), 
lipoprotein-associated phospholipase A2 (Lp-
PLA2) and IL-1β. p38 MAPK is a proinflammatory 
stress-activated kinase present in macrophages, 
endothelial and myocardial cells, which among 
other mechanisms contributes to the amplifica-
tion of the inflammatory cascade by promoting the 
release of cytokines, such as TNFα, IL-1 and IL-6. 
In a randomised placebo-controlled trial, the effects 
of the p38 MAPK inhibitor losmapimod on arte-
rial inflammation were evaluated using 18F-FDG 
PET imaging in 99 patients with atherosclerosis 
who were also treated with statins.87 In this study, 
there was no significant difference detected in the 
primary endpoint of generalised vascular 18F-FDG 
uptake, although losmapimod did dampen 18F-FDG 
uptake in the most actively inflamed regions.87 In a 
subsequent clinical outcome trial including ~22 000 
patients with acute MI, this drug did not signifi-
cantly reduce the risk of major ischaemic cardio-
vascular events compared with placebo during 
the 12-week follow-up.88 In a study of another 
p38 MAPK inhibitor, BMS-582949, carotid and 
aortic 18F-FDG inflammatory signals were also not 
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significantly lowered by this drug in patients with 
stable atherosclerosis receiving low-dose statins.89
Lipoprotein-associated phospholipase A 2 
(Lp-PLA2) is another pharmacotherapeutic target that 
has been tested in cardiovascular disease. Increased 
Lp-PLA2 activity is associated with greater cardio-
vascular risk90 and, in preclinical studies, Lp-PLA2 
inhibition has been shown to exert plaque stabilising 
effects mediated via anti-inflammatory actions on 
multiple genes associated with macrophage and T 
lymphocyte functioning.91 However, in a randomised 
placebo-controlled study of 83 patients with stable 
atherosclerosis imaged using 18F-FDG PET, the 
Lp-PLA2 inhibitor rilapladib showed no significant 
difference in the primary and secondary imaging 
end-points comparing vascular inflammation between 
treatment groups.92 Similarly, in another study, the 
Lp-PLA2 inhibitor darapladib failed to reduce coro-
nary atheroma deformability (a marker of mechan-
ical cap stress and plaque vulnerability) using IVUS 
palpography but did halt necrotic core expansion 
compared with placebo.93 Darapladib also did not 
significantly reduce the risk of MI, stroke or death 
in a randomised placebo-controlled trial of 15 828 
patients with stable coronary disease followed up for 
3.7 years,94 nor did it reduce major coronary events 
in a randomised, placebo-controlled trial of 13 026 
patients followed up for 2.5 years after an acute coro-
nary syndrome.95
Canakinumab is a human monoclonal antibody 
that inhibits IL-1β, a cytokine central to the acute 
inflammatory response that drives the classical IL-6 
pathway. In a study of 189 individuals with atheroscle-
rosis and type 2 diabetes mellitus or impaired glucose 
tolerance, there was no significant difference in mean 
carotid wall area on MRI observed after 12 months 
of drug treatment compared with placebo, despite 
measureable effects on hsCRP and IL-6.96 However, 
in a clinical outcome trial including 10 061 patients 
with previous history of MI and hsCRP >2 mg/L 
treated with canakinumab in addition to usual 
therapy, there was a significantly lower incidence 
of recurrent cardiovascular events compared with 
placebo.97 Further work is needed to fully evaluate 
the role of this, and other, anti-inflammatory drugs 
for the treatment of atherosclerosis.
figure 5 Use of surrogate imaging markers to evaluate dalcetrapib. Graphs showing nominal changes in (A) arterial 18F-FDG inflammatory signals 
(7% reduction, p=0.08) in the most inflamed regions and (B) carotid total vessel area (4 mm2 reduction; p=0.04) in a double-blind multicentre trial 
of 130 patients randomised to treatment with the cholesteryl ester transfer protein inhibitor dalcetrapib (green dots) versus placebo (red dots). In 
a substudy of the same trial, (C) the difference in carotid 18F-FDG signal intensity between dalcetrapib (blue dots) and placebo (red squares) was 
more apparent in patients without carotid calcification (p<0.001). However, lack of data showing a clear, consistent effect of dalcetrapib on these 
surrogate imaging markers predicted its inability to reduce recurrent cardiovascular events in patients with acute coronary syndrome in a large clinical 
outcome trial; (D) graph showing similar rates of cardiovascular events for dalcetrapib versus placebo in this study. Figure adapted from Fayad et al. 
Lancet 2011 (A and B);73 Joshi et al. J Am Coll Cardiol 2016 (C);74 Schwartz et al. N Eng J Med 2012 (D).75 MDS TBR,Most Diseased Segment Target-to-
Background Ratio.
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ConCLusIon
While we have many imaging strategies that can be 
applied as surrogate markers of drug efficacy, none 
of these methods can surpass the benchmark of a 
clinical outcome trial. However, imaging can be 
used to elucidate mechanisms of action and directly 
quantify specific drug effects on the arterial wall and 
atherosclerotic plaques. As we begin to see the clinical 
introduction of a range of novel antiatherosclerosis 
therapies to treat the many patients with so-called 
residual lipid or inflammatory burden, imaging can 
be used to help fast-track those drugs most likely to 
have a real clinical impact into large-scale phase III 
trials and to avoid wasting vast resources on drugs 
that have no measureable effect on any of the estab-
lished markers of disease severity.
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Key messages
 ► The use of imaging in clinical cardiovascular drug trials can impart valuable 
insights into underlying mechanisms of action and early evidence of drug 
efficacy to improve the efficiency of subsequent clinical outcome studies.
 ► Measurements of plaque burden are among the most useful surrogate 
imaging markers in cardiovascular disease, as this marker exhibits the 
strongest relationship with hard clinical outcomes.
 ► However, as modest changes in plaque burden occurring in response 
to lipid-lowering therapy do not match the large reductions in clinical 
outcomes observed in randomised trials, other mechanisms related to 
plaque composition and inflammation should also be considered for use as 
surrogate endpoints.
 ► Imaging endpoints cannot replace the need for large-scale clinical outcome 
studies to evaluate the true clinical value and safety of a new drug.
 ► Imaging studies have demonstrated that statins can dampen arterial 
inflammation, induce plaque regression and exert stabilising effects on 
plaque morphology and the degree of coronary macrocalcification.
 ► Imaging has also been used to test the effects of other cholesterol-modifying 
therapies, as well as anti-inflammatory therapies, on the arterial wall and 
atherosclerotic plaques.
figure 6 Effect of evolucumab on plaque volume versus low-density lipoprotein cholesterol (LDL-c). Graph showing the change in per cent 
atheroma volume measured by intravascular ultrasound in a study of evaluating the effects of aggressive LDL-c lowering with the proprotein 
convertase subtilisin-kexin 9 inhibitor evolucumab in statin-treated patients. Figure from Nicholls et al. JAMA 2016.76
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